Patents Examined by David W Berke-Schlessel
-
Patent number: 11976295Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.Type: GrantFiled: January 12, 2023Date of Patent: May 7, 2024Assignee: MINERVA BIOTECHNOLOGIES CORPORATIONInventors: Cynthia Bamdad, Benoit Smagghe
-
Patent number: 11976298Abstract: Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.Type: GrantFiled: September 19, 2018Date of Patent: May 7, 2024Assignee: Targazyme, Inc.Inventors: Stephen D. Wolpe, Leonard Miller, Lynnet Koh, Thomas E. Ichim
-
Patent number: 11975027Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.Type: GrantFiled: November 30, 2021Date of Patent: May 7, 2024Assignee: ImmunityBio, Inc.Inventors: Hans G. Klingemann, Barry J. Simon
-
Patent number: 11970724Abstract: The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest.Type: GrantFiled: July 8, 2021Date of Patent: April 30, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Shadia Abike Oshodi, Amy S. Johnson, Shawn M. Lawrence
-
Patent number: 11965199Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: GrantFiled: January 31, 2022Date of Patent: April 23, 2024Assignee: SANOFIInventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Patent number: 11952559Abstract: This present disclosure relates to novel detergent compositions comprising bacterial mannanase enzymes. The detergent compositions comprising bacterial mannanases are useful in laundry and cleaning applications wherein degradation or modification of mannan is desired. The present disclosure also relates to the use of said detergent compositions in laundry and cleaning applications as well as a method for degrading mannan.Type: GrantFiled: March 1, 2018Date of Patent: April 9, 2024Assignee: AB Enzymes OyInventors: Daniela Herbst, Susanne Wieland, Nina Mussmann, Taija Leinonen, Leena Valtakari, Michael Seefried, Kari Juntunen, Daniela Dollak, Patrick Lorenz, Jari Vehmaanperae, Pentti Ojapalo, Terhi Puranen, Kristiina Jaervinen
-
Patent number: 11952592Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.Type: GrantFiled: February 23, 2022Date of Patent: April 9, 2024Assignee: EMULATE, INC.Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
-
Patent number: 11952603Abstract: A pancreatin preparation having reduced viral infectivity includes one or more pancreatin enzymes and peracetic acid (PAA). At least one pancreatin enzyme may be derived from an animal source such as a porcine pancreas gland. In a particular embodiment, the one or more pancreatin enzymes are selected from the group consisting of lipases, proteases, and amylases.Type: GrantFiled: August 22, 2018Date of Patent: April 9, 2024Assignee: SCIENTIFIC PROTEIN LABORATORIES, LLCInventors: Kenneth S. Manning, Yan Wang, Dustin Nielsen, Ryan Ruf, Colin Crowley, Jon Restivo, Dana Spangenberg, Karla Anhalt, Mark Romich, Anisha Akula, Carmen Fritz
-
Patent number: 11944651Abstract: The present invention aims to provide an antimicrobial and antiviral agent which comprises a naturally occurring component as an active ingredient and is effective against microbes including various classes of fungi and viruses. In one aspect of the present invention, provided is an antimicrobial and antiviral agent comprising Lactobacillus derived from Artemisia indica var. maximowiczii.Type: GrantFiled: September 8, 2021Date of Patent: April 2, 2024Assignee: Murata Manufacturing Co., Ltd.Inventors: Masachika Takata, Hirofumi Sunahara
-
Patent number: 11944654Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.Type: GrantFiled: August 11, 2022Date of Patent: April 2, 2024Assignee: Rebiotix, Inc.Inventor: Edwin J. Hlavka
-
Patent number: 11945795Abstract: Disclosed herein are compositions and methods useful for manufacturing SC-? cell, and isolated populations of SC-? cells for use in various applications, such as cell therapy.Type: GrantFiled: May 1, 2020Date of Patent: April 2, 2024Assignee: Vertex Pharmaceuticals IncorporatedInventors: Austin Thiel, Jihad Yasin, Evrett Thompson, Felicia J. Pagliuca
-
Patent number: 11946853Abstract: A apparatus for detecting cells or particles in a fluid container includes a dispenser configured to dispense at least one cell or at least one particle into a defined sub-volume of a fluid with which the fluid container is at least partially filled, and a detection apparatus configured to, in a time-coordinated manner with dispensing the at least one cell or the at least one particle by the dispenser, perform a detection in the defined sub-volume and/or in one or several sub-volumes underneath the defined sub-volume in order to sense the at least one cell or the at least one particle when entering the fluid or immediately after entering the fluid.Type: GrantFiled: August 6, 2021Date of Patent: April 2, 2024Assignee: cytena GmbHInventors: Jonas Schoendube, Andre Gross
-
Patent number: 11940442Abstract: The current technology is related to methods for rapidly determining the metabolic baseline and potential of living cells. Embodiments relate to measuring the activity of each of the two major energy-generating pathways within the cell: mitochondrial respiration and glycolysis, first under baseline conditions, and again after applying a stress to the cells to demand increased energy supply. In some embodiments the stress may be applied by exposing the cells to a combination of two chemical compounds: a mitochondrial uncoupler and an ATP synthase inhibitor. In one embodiment, the metabolic energy generating activity of the mitochondrial respiration pathway is determined by measuring the rate of oxygen consumption by the living cells, and the metabolic energy generating activity of the glycolysis pathway is determined from a measurement of extracellular acidification caused by secretion of protons from the cell.Type: GrantFiled: June 30, 2020Date of Patent: March 26, 2024Assignee: Agilent Technologies, Inc.Inventors: David A. Ferrick, Brian Dranka
-
Patent number: 11938125Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.Type: GrantFiled: March 7, 2022Date of Patent: March 26, 2024Assignee: ZEVRA DENMARK A/SInventors: Thomas Kirkegaard Jensen, Marja H. Jaattela
-
Patent number: 11930823Abstract: The present specification discloses pest control compositions, articles of manufacture, containers or kits comprising such compositions, and methods and uses to control a population of invertebrate pests from a mammal, location, plant, structure treated of such pest control compositions.Type: GrantFiled: September 4, 2021Date of Patent: March 19, 2024Assignee: Neozyme International, Inc.Inventors: Parker Dale, Parker David Dale
-
Patent number: 11933790Abstract: A method of isotope-labelling a microbiota sample. It involves providing a first microbiota sample that was obtained from a given source; exposing the first microbiota sample to an isotope enriched medium; and culturing the exposed first microbiota sample in the isotope enriched medium to obtain an isotope-labelled microbiota sample, wherein the isotope labelled metaproteome of the isotope-labelled microbiota sample is taxon specific for taxa present in the first microbiota sample when initially obtained from the given source.Type: GrantFiled: January 27, 2021Date of Patent: March 19, 2024Assignee: UNIVERSITY OF OTTAWAInventors: Joseph Michel Daniel Figeys, Alain Christophe Stintzi, David R. Mack, Xu Zhang, Zhibin Ning
-
Patent number: 11926854Abstract: The present invention relates to fusion proteins comprising an N-intein polypeptide and an N-intein solubilization partner, and affinity chromatography matrices comprising such fusion proteins, as well as methods of using same.Type: GrantFiled: April 13, 2022Date of Patent: March 12, 2024Assignee: Merck Patent GmbHInventors: Martin Zillmann, Joe Orlando
-
Patent number: 11918608Abstract: Provided herein are methods of treating EIPH in a subject in need thereof. The methods comprise administering an effective amount of a pharmaceutical composition to the subject. In some embodiments, the pharmaceutical composition comprises a granuloma fluid, or a composition derived from a granuloma fluid. In some embodiments, the pharmaceutical composition comprises a cell. These pharmaceutical compositions may be administered by any suitable route of administration, and may be administered with one or more further therapeutic agents. Also provided are kits comprising pharmaceutical compositions for use with the methods provided herein.Type: GrantFiled: January 14, 2021Date of Patent: March 5, 2024Assignee: RECELLERATE, INC.Inventor: Karl Nobert
-
Patent number: 11920158Abstract: A cardiomyocyte maturation medium comprises a base medium, one or more fatty acids such as palmitic acid, glucose and albumin. The one or more fatty acids and glucose are ideally present at a concentration ratio of about 1:10. Typically, the medium does not comprise TGF or insulin, or comprises minimal TGF and/or insulin. A cell culture vessel is provided that comprises opposed poles that facilitate force measurements of developing cardiac muscle.Type: GrantFiled: August 25, 2017Date of Patent: March 5, 2024Assignee: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCHInventors: Enzo Porrello, James Hudson, Drew Titmarsh, Richard Mills
-
Patent number: 11918705Abstract: A method of making an electron beam irradiated osteoinductive implant is provided. The method comprises exposing an osteoinductive implant containing demineralized bone matrix (DBM) fibers to electron beam radiation at a dose of from about 10 kilograys to 100 kilograys for a period of time. The electron beam irradiation reduces microorganisms in the osteoinductive implant, and the electron beam irradiated osteoinductive implant retains osteoinductive properties. Methods of implantation and an irradiated osteoinductive implant are also disclosed.Type: GrantFiled: August 16, 2021Date of Patent: March 5, 2024Assignee: Warsaw Orthopedic, Inc.Inventors: Kelly W. Schlachter, Erick Vasquez, Daniel A. Shimko